TeklaLife Sciences Investors

19.53+0.2500+1.30%Vol 99.36K1Y Perf 25.26%
Apr 13th, 2021 15:53 DELAYED
BID19.50 ASK19.54
Open19.37 Previous Close19.28
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap444.50M 
Earnings Rating
Price Range Ratio 52W %
57.27 
Earnings Date
-

Today's Price Range

19.2619.67

52W Range

15.7922.32

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.97%
1 Month
-4.70%
3 Months
-5.72%
6 Months
4.84%
1 Year
25.26%
3 Years
0.84%
5 Years
0.16%
10 Years
134.34%

TickerPriceChg.Chg.%
HQL19.530.25001.30
AAPL134.443.20002.44
GOOG2 273.2018.41000.82
MSFT258.342.43000.95
XOM55.700.20000.36
WFC39.85-0.9200-2.26
JNJ159.44-2.2000-1.36
FB309.96-1.5800-0.51
GE13.48-0.1100-0.81
JPM154.37-1.5800-1.01
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume99.36K
Shares Outstanding22.76M
Trades Count503
Dollar Volume1.87M
Avg. Volume85.86K
Avg. Weekly Volume103.79K
Avg. Monthly Volume89.00K
Avg. Quarterly Volume87.11K

TeklaLife Sciences Investors (NYSE: HQL) stock closed at 19.28 per share at the end of the most recent trading day (a -1.28% change compared to the prior day closing price) with a volume of 154.36K shares and market capitalization of 444.50M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Asset Management industry, Financial Services sector and employs 0 people. TeklaLife Sciences Investors CEO is .

The one-year performance of TeklaLife Sciences Investors stock is 25.26%, while year-to-date (YTD) performance is -2.38%. HQL stock has a five-year performance of 0.16%. Its 52-week range is between 15.79 and 22.32, which gives HQL stock a 52-week price range ratio of 57.27%

TeklaLife Sciences Investors currently has a PE ratio of 3.80, a price-to-book (PB) ratio of 0.96, a price-to-sale (PS) ratio of 5.01, a price to cashflow ratio of 17.30, a PEG ratio of 2.32, a ROA of 28.25%, a ROC of -% and a ROE of 28.38%. The company’s profit margin is 99.46%, its EBITDA margin is -%, and its revenue ttm is $93.37 Million , which makes it $3.85 revenue per share.

Of the last four earnings reports from TeklaLife Sciences Investors, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. TeklaLife Sciences Investors’s next earnings report date is -.

The consensus rating of Wall Street analysts for TeklaLife Sciences Investors is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for TeklaLife Sciences Investors stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

TeklaLife Sciences Investors has a dividend yield of 8.17% with a dividend per share of $1.58 and a payout ratio of 407.00%.

TeklaLife Sciences Investors has a Sell technical analysis rating based on Technical Indicators (ADX : 14.48, ATR14 : 0.62, CCI20 : -115.32, Chaikin Money Flow : -0.28, MACD : -0.35, Money Flow Index : 41.82, ROC : -1.98, RSI : 36.86, STOCH (14,3) : 0.00, STOCH RSI : 0.52, UO : 28.04, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of TeklaLife Sciences Investors in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

TeklaLife Sciences Investors

Tekla Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in the securities of life sciences companies. The fund invests in the securities of public and private companies.

CEO:

Telephone: +1 617 772-8500

Address: 100 Federal Street, Boston 02110, MA, US

Number of employees: 0

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

75%25%

Bearish Bullish

55%45%

News

Stocktwits